# 2025-18075: FDA Hikes Fee for Fast-Tracking Tropical Disease Drugs in 2026

2025-18075, Fee Rate for Using a Priority Review Voucher in Fiscal Year 2026, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-09-18, effective 2025-10-01; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-18075
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-18075
- Title: Fee Rate for Using a Priority Review Voucher in Fiscal Year 2026
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 45041
- Published: 2025-09-18
- Effective: 2025-10-01
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Hikes Fee for Fast-Tracking Tropical Disease Drugs in 2026

## Summary

The FDA is setting the fee for using a priority review voucher in fiscal year 2026. This affects companies with special drug applications for rare diseases, tropical diseases, or medical threats who want faster reviews. The fee is based on last year’s review costs, so get ready to pay the updated price when you submit your application next year!

## Abstract

The Food and Drug Administration (FDA or the Agency) is announcing the fee rate for using a priority review voucher for fiscal year (FY) 2026. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended, authorizes FDA to determine and collect priority review user fees for certain applications for review of human drug or biological products when those applications use a tropical disease, rare pediatric disease, or material threat medical countermeasure (MCM) priority review voucher. These vouchers are awarded to the sponsors of tropical disease, rare pediatric disease, or material threat MCM product applications, respectively, that meet the requirements of the FD&C Act, upon FDA approval of such applications. The amount of the fee for using a priority review voucher is determined each fiscal year, based on the difference between the average cost incurred by FDA to review a human drug application designated as priority review in the previous fiscal year, and the average cost incurred in the review of an application that is not subject to priority review in the previous fiscal year. This notice establishes the FY 2026 priority review fee rate applicable to submission of eligible applications for review of human drug or biological products using a rare pediatric disease, material threat MCM, or tropical disease priority review voucher and outlines the payment procedures for such fees.

## Effects PRIA read

- FY2026 Priority Review Voucher Fee: cost, medium. If your company plans to use a Priority Review Voucher in fiscal year 2026, the FDA has set the fee you must pay when you submit a human drug or biological product application. The fee applies to applications using rare pediatric disease, material threat medical countermeasure (MCM), or tropical di…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-18075 on federalregister.gov](https://www.federalregister.gov/documents/2025/09/18/2025-18075/fee-rate-for-using-a-priority-review-voucher-in-fiscal-year-2026)
- [2025-18075 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-09-18/pdf/2025-18075.pdf)

## Related
- [Previous: 2025-18074, Sunshine Act Meeting Notice](https://policyrisk.com/federal-register/2025-18074)
- [Next: 2025-18076, Sunshine Act Meetings](https://policyrisk.com/federal-register/2025-18076)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-18075 (as of 2026-06-08).
